Next Article in Journal
Matching Mechanics and Energetics of Muscle Contraction Suggests Unconventional Chemomechanical Coupling during the Actin–Myosin Interaction
Next Article in Special Issue
DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic Leukemia: Focus on the Genes Involved
Previous Article in Journal
Salivary Oxytocin and Antioxidative Response to Robotic Touch in Adults with Autism Spectrum Disorder
Previous Article in Special Issue
The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches
 
 
Article
Peer-Review Record

Significance of Th17 and Treg in Treatment Efficacy and Outcome in Pediatric Acute Lymphoblastic Leukemia

Int. J. Mol. Sci. 2023, 24(15), 12323; https://doi.org/10.3390/ijms241512323
by Anna Krętowska-Grunwald 1,2,*, Małgorzata Sawicka-Żukowska 1, Małgorzata Kowalska 3, Aleksandra Basaj 4, Maryna Krawczuk-Rybak 1, Marcin Moniuszko 2,5 and Kamil Grubczak 2,*
Reviewer 1: Anonymous
Int. J. Mol. Sci. 2023, 24(15), 12323; https://doi.org/10.3390/ijms241512323
Submission received: 8 July 2023 / Revised: 26 July 2023 / Accepted: 27 July 2023 / Published: 1 August 2023
(This article belongs to the Special Issue New Insights in Tumor Immunity)

Round 1

Reviewer 1 Report

This manuscript addresses a topic that can be of interest to readers. It is clearly organized and based on good hypotheses. The work is convincing although some minor points need to be discussed.

1. Flow cytometric detection of Th17 and Treg: What was used for assessment? Mononuclear cells (If so, how were they isolated?), whole blood or whole bone marrow?

2. Flow cytometry: There is no mention of important details such as how the flow cytometer was set up, quality control and compensation. How was the data verified? In particular, intracellular staining by flow cytometry is difficult and can often lead to false positives. Authors should provide a variety of controls (ie. cells unstained, isotype control, etc). How many cells were processed?

3. Mention, whether the ELISA assays were carried out in duplicates for each sample.

4. Results: Authors should better describe the analysis performed, the number of cases/samples analyzed for each parameter, and the statistical analysis results (median, range, IQR...).

5. Figure 3.: The authors divided the cohort into two groups: low and high. What were the cutoff values? Some explanation is necessary in the main text.

6. All abbreviations should be defined.

7. There are a few grammatical and typo errors which must be corrected.

 

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

A nice, interesting, and well-written artcile, exploring the role of a few inflammatory chemokines and the related cells in ALL.

I have only a few minor observation:

1) Lane 291: frequencies...of what? please rephrase as not very clear for the reader

2) The levels of cytokines and cell populations were evaluated along the disease course. It would be nice to see a comparison between, patients achieving CR vs. no; deep CR (no MRD) vs no CR ; and then see whether patients in CR but still higher values did relapse more frequently (relapse rate in Higher vs lower levels/frequencies)

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop